FutureChem's 40 Billion Won Rights Offering and 20% Free Stock Issuance Becomes Effective, Diluting Existing Shareholders by 15.1% and Reducing Majority Stake to Below 11%
The securities registration statement filed on June 15, 2026 became effective on June 30, 2026, finalizing the 40 billion won rights offering and 20% free stock issuance.
The rights offering issues 3,389,830 new common shares, diluting existing shareholders by 15.1%, and the free issuance increases total shares to 30,980,700.
Proceeds will be allocated to R&D including 9.1 billion won for domestic Phase 3 trial of prostate cancer therapy FC705, 4.26 billion won for US Phase 2b trial, and 7.19 billion won for indication expansion trials.
The combined stake of CEO Ji Daeyoon and related parties drops to 10.21% after the offering, potentially declining further to 10.08% upon conversion of convertible bonds and exercise of stock options, raising governance concerns.
The company reported an operating loss of 7.75 billion won and net loss of 11.2 billion won in 2025, with negative operating cash flow, signaling weak financial health.
Outstanding convertible bonds of 3.53 billion won and convertible preferred shares of 1.2 billion won may lead to additional dilution if conversion prices are adjusted downward.
The company holds 5,227 treasury shares but has no plans for cancellation or additional buybacks; no separate shareholder return policy has been disclosed.
[AI Summary]The effectiveness confirmation finalizes a 15% dilution overhang, pressuring the stock price in the short term. While funds are directed toward critical clinical programs, persistent operating losses and a declining majority stake increase business uncertainty. Investors should closely monitor clinical outcomes and potential future capital needs.
KOSDAQ Filing Information
Effectiveness Notice (Securities Registration Statement (Equity Securities) Submitted On June 15, 2026)